

CITATION REPORT

List of articles citing

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)

DOI: 10.1158/1078-0432.ccr-16-3155
Clinical Cancer Research, 2017, 23, 5416-5425.

Source: <https://exaly.com/paper-pdf/67620190/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
168	Review of Blood-Based Colorectal Cancer Screening: How Far Are Circulating Cell-Free DNA Methylation Markers From Clinical Implementation?. 2018 , 17, e415-e433		32
167	Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients. 2018 , 17, e369-e379		30
166	Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. 2018 , 9, 896		197
165	BIABooster: Online DNA Concentration and Size Profiling with a Limit of Detection of 10 fg/μl and Application to High-Sensitivity Characterization of Circulating Cell-Free DNA. 2018 , 90, 3766-3774		25
164	Role of circulating tumor DNA in the management of patients with colorectal cancer. 2018 , 42, 396-402		11
163	Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime?. <i>Annals of Oncology</i> , 2018 , 29, 532-534	10.3	3
162	RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGE0 RASANC prospective multicenter study. <i>Annals of Oncology</i> , 2018 , 29, 1211-1219	10.3	84
161	Extracellular vesicles or free circulating DNA: where to search for BRAF and cKIT mutations?. 2018 , 14, 875-882		17
160	Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. 2018 , 23, 1310-1318		32
159	Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study. <i>British Journal of Cancer</i> , 2018 , 118, 1217-1228	8.7	35
158	Circulating tumour DNA, a promising biomarker for the management of colorectal cancer. 2018 , 122, 72-82		29
157	Liquid biopsies in gastrointestinal malignancies: when is the big day?. 2018 , 18, 19-38		20
156	Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. 2018 , 18, 7-17		102
155	Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1464-1470	8.7	40
154	Tumor-specific methylations in circulating cell-free DNA as clinically applicable markers with potential to substitute mutational analyses. 2018 , 18, 1011-1019		7
153	The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy. <i>Frontiers in Oncology</i> , 2018 , 8, 610	5.3	5
152	Liquid Biopsy in Gastrointestinal Cancers. 2018 , 8,		8

151	Molecular Diagnostics in Clinical Oncology. 2018 , 5, 76		64
150	Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer. 2018 , 17, 2238-2247		17
149	Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma. 2018 , 37, 55		19
148	The Use of Circulating Tumor DNA for Prognosis of Gastrointestinal Cancers. <i>Frontiers in Oncology</i> , 2018 , 8, 275	5.3	19
147	[Circulating tumour DNA: Current detection methods, use in radiotherapy and future development]. 2018 , 22, 653-659		1
146	Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer. 2019 , 9, 11542		13
145	How liquid biopsies can change clinical practice in oncology. <i>Annals of Oncology</i> , 2019 , 30, 1580-1590	10.3	107
144	Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGE0 RASANC Study. <i>Cancers</i> , 2019 , 11,	6.6	11
143	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. 2019 , 79, 1375-1394		29
142	Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements. 2019 , 8,		40
141	Microfluidic extraction and digital quantification of circulating cell-free DNA from serum. 2019 , 286, 533-539		24
140	Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer. 2019 , 29, 3871-3880		6
139	Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer. 2019 , 26, 1824-1832		21
138	Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response. <i>Frontiers in Genetics</i> , 2019 , 10, 470	4.5	23
137	Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodiges-14 Trial. 2019 , 8,		40
136	Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 6026-6034	12.9	27
135	Liquid Biopsy: General Concepts. 2019 , 63, 449-455		89
134	State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA. 2019 , 133-188		1

133	ASO Author Reflections: Perioperative Genomic Profiles and Prognosis of Peripheral and Perihepatic Circulating Tumor DNA in Patients with Colorectal Liver Metastases. 2019 , 26, 583-584		
132	A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer. 2019 , 24, 883-e407		32
131	The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis. 2019 , 18, 36		34
130	How to better select patients with advanced gastric cancer for immunotherapy. 2019 , 4, 6		4
129	Recent advances in circulating nucleic acids in oncology. <i>Annals of Oncology</i> , 2019 , 30, 374-384	10.3	45
128	Detection of ctDNA in the plasma of patients with papillary thyroid carcinoma. 2019 , 18, 3389-3396		3
127	Correlation Between Tumor-Specific Mutated and Methylated DNA in Colorectal Cancer.. 2019 , 3, 1-8		2
126	Mutant Allele Fraction in Circulating Cell-Free DNA Correlates With Clinical Stage in Pancreatic Cancer Patients. <i>Frontiers in Oncology</i> , 2019 , 9, 1295	5.3	20
125	Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 1414	5.3	4
124	Current Utility and Future Applications of ctDNA in Colorectal Cancer. 2019 ,		
123	The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer. <i>Frontiers in Genetics</i> , 2019 , 10, 1118	4.5	39
122	Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management. 2019 , 1909, 47-73		14
121	Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. 2019 , 79, 1204-1213		50
120	RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. 2019 , 72, 135-139		17
119	Tumor Liquid Biopsies. <i>Recent Results in Cancer Research</i> , 2020 ,	1.5	5
118	Technical progress in circulating tumor DNA analysis using next generation sequencing. 2020 , 49, 101480		10
117	Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study. <i>Clinical Cancer Research</i> , 2020 , 26, 397-407	12.9	33
116	Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer. 2020 , 147, 1185-1189		14

115	Circulating Tumor DNA in KRAS positive colorectal cancer patients as a prognostic factor - a systematic review and meta-analysis. 2020 , 154, 103065		6
114	Recent technologies enhancing the clinical utility of circulating tumor DNA. 2020 , 510, 498-506		1
113	ctDNA as a cancer biomarker: A broad overview. 2020 , 155, 103109		30
112	Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer. <i>Carcinogenesis</i> , 2020 , 41, 1507-1517	4.6	6
111	Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with -Mutant Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6242-6253	12.9	10
110	On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer. 2020 , 4, 30		4
109	Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma. 2020 , 8, 179		7
108	Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood: An Observational Prospective Study. 2020 , 22, 920-933		5
107	Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	15
106	Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy. 2020 , 25, 1523-1532		9
105	Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy. 2020 , 39, 999-1013		18
104	"Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial". 2020 , 52, 730-733		6
103	Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer. 2020 , 25, e1188-e1194		24
102	MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy. 2020 , 9,		30
101	Prognostic Value of Serum NPY Hypermethylation in Neoadjuvant Chemoradiotherapy for Rectal Cancer: Secondary Analysis of a Randomized Trial. 2020 , 43, 9-13		6
100	Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920918472	5.4	13
99	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. 2020 , 20, 251-270		3
98	Redefining Colorectal Cancer by Tumor Biology. 2020 , 40, 1-13		3

97	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. 2020 , 17, 757-770		82
96	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. <i>British Journal of Cancer</i> , 2020 , 122, 957-962	8.7	2
95	Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 4010-4017	12.9	8
94	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2020 , 26, 1877-1885	12.9	28
93	Circulating tumor-specific DNA: a stony road to clinical utility. 2020 , 14, 331-333		
92	Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. 2021 , 113, 309-317		19
91	The Application of Circulating Tumor DNA in the Screening, Surveillance, and Treatment Monitoring of Colorectal Cancer. 2021 , 28, 1845-1858		4
90	Liquid biopsies: Potential and challenges. 2021 , 148, 528-545		50
89	Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. 2021 , 71, 176-190		31
88	Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021 , 144, 368-381	7.5	11
87	Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. 2021 , 7, 8		2
86	Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. 2021 , 53, 318-323		4
85	Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA. 2021 , 16, 309-324		2
84	Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients. 2021 , 23, 31		9
83	Early dynamics of circulating tumor DNA predict chemotherapy responses for patients with esophageal cancer.		
82	Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. 2021 ,		1
81	The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer. 2021 , 27, 942-952		1
80	Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System. <i>Cancers</i> , 2021 , 13,	6.6	2

79	Olfactory Detection of Toluene by Detection Rats for Potential Screening of Lung Cancer. 2021 , 21,		1
78	Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. 2021 , 45, 101681		
77	Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer. 2021 , 149, 1385-1397		1
76	Characterization of Plasma Cell-Free DNA Integrity Using Droplet-Based Digital PCR: Toward the Development of Circulating Tumor DNA-Dedicated Assays. <i>Frontiers in Oncology</i> , 2021 , 11, 639675	5.3	1
75	Clinical Implication of Liquid Biopsy in Colorectal Cancer Patients Treated with Metastasectomy. <i>Cancers</i> , 2021 , 13,	6.6	2
74	Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival. <i>European Journal of Cancer</i> , 2021 , 149, 128-133	7.5	4
73	Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Analysis of the PRODIGE-GERCOR IDEA-France Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 5638-5646	12.9	11
72	CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC). <i>British Journal of Cancer</i> , 2021 , 125, 725-733	8.7	1
71	Perspectives for circulating tumor DNA in clinical management of colorectal cancer. 2021 , 26, 1420-1430		0
70	Comparing immunotherapies to other frequently used treatments of gastric cancer. 2021 , 14, 1221-1232		0
69	Mutational landscape of plasma cell-free DNA identifies molecular features associated with therapeutic response in patients with colon cancer. A pilot study. 2021 , 36, 358-368		1
68	Association of emergence of new mutations in circulating tumor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer. <i>BMC Cancer</i> , 2021 , 21, 845	4.8	
67	Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA). <i>Lung Cancer</i> , 2021 , 157, 124-130	5.9	2
66	Treatment with encorafenib and cetuximab of a non-anti-epidermal growth factor receptor-naive patient for BRAF V600E-mutated metastatic colon cancer. <i>European Journal of Cancer</i> , 2021 , 152, 1-3	7.5	1
65	Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study. <i>PLoS Medicine</i> , 2021 , 18, e1003741	11.6	11
64	Content of circulating tumor DNA depends on the tumor type and the dynamics of tumor size, but is not influenced significantly by physical exercise, time of the day or recent meal. <i>Cancer Genetics</i> , 2021 , 256-257, 165-178	2.3	1
63	Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives. <i>Cancers</i> , 2021 , 13,	6.6	3
62	Detection and utility of cell-free and circulating tumour DNA in bone and soft-tissue sarcomas. <i>Bone and Joint Research</i> , 2021 , 10, 602-610	4.2	1

61	Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as a Liquid Biopsy Marker in Colorectal Cancer. <i>Cancers</i> , 2021 , 13,	6.6	1
60	Early dynamics of circulating tumor DNA predict chemotherapy responses for patients with esophageal cancer. <i>Carcinogenesis</i> , 2021 , 42, 1239-1249	4.6	3
59	Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer. <i>Cancers</i> , 2021 , 13,	6.6	1
58	A one step method for isolation of genomic DNA using multi-amino modified magnetic nanoparticles.. <i>RSC Advances</i> , 2021 , 11, 3324-3332	3.7	1
57	Clinical Perspectives on Liquid Biopsy in Metastatic Colorectal Cancer. <i>Frontiers in Genetics</i> , 2021 , 12, 634642	4.5	2
56	Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases. <i>Theranostics</i> , 2021 , 11, 7018-7028	12.1	6
55	Cell-Free DNA in the Management of Colorectal Cancer. <i>Recent Results in Cancer Research</i> , 2020 , 215, 253-261	1.5	1
54	Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. <i>Gut</i> , 2018 , 67, 1995-2005	19.2	119
53	Coupling multiplex pre-amplification and droplet digital PCR for longitudinal monitoring of ESR1 and PIK3CA mutations from plasma cell-free DNA.		
52	LADN tumoral circulant dans le cancer colorectal. <i>Colon and Rectum</i> , 2019 , 13, 98-101	0	
51	THE IMPORTANCE OF CIRCULATING TUMOR DNA IN THE ASSESSMENT OF METASTATIC COLORECTAL CANCER TREATMENT EFFECTIVNE. <i>Siberian Journal of Oncology</i> , 2021 , 20, 149-161	0.3	
50	Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). <i>European Journal of Cancer</i> , 2021 , 159, 24-33	7.5	2
49	Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?. <i>Current Oncology Reports</i> , 2021 , 23, 140	6.3	1
48	Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359211070643	5.4	0
47	Clonal Hematopoiesis and Liquid Biopsy in Gastrointestinal Cancers.. <i>Frontiers in Medicine</i> , 2021 , 8, 772166	6.9	0
46	Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma.. <i>Clinical Chemistry</i> , 2022 ,	5.5	1
45	Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.. <i>European Journal of Cancer</i> , 2022 , 163, 163-176	7.5	3
44	Clinical Validity of Circulating Tumor DNA as Prognostic and Predictive Marker for Personalized Colorectal Cancer Patient Management.. <i>Cancers</i> , 2022 , 14,	6.6	0

43	Combined detection of stool-based methylation indicators for early screening of colorectal neoplasm. <i>American Journal of Translational Research (discontinued)</i> , 2021 , 13, 11597-11607	3	
42	Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy.. <i>Frontiers in Oncology</i> , 2022 , 12, 830816	5.3	
41	Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases.. <i>Journal of the American College of Surgeons</i> , 2022 , 234, 474-483	4.4	3
40	Reporting on circulating tumor DNA monitoring in metastatic cancer-From clinical validity to clinical utility.. <i>Cancer</i> , 2022 ,	6.4	0
39	Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis.. <i>British Journal of Cancer</i> , 2022 ,	8.7	3
38	Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	2
37	DataSheet_1.docx. 2019 ,		
36	Image_1.TIF. 2019 ,		
35	Image_2.TIF. 2019 ,		
34	Image_3.TIF. 2019 ,		
33	Image_4.TIF. 2019 ,		
32	Presentation_1.pdf. 2019 ,		
31	Table_1.DOCX. 2019 ,		
30	Table_2.DOCX. 2019 ,		
29	Data_Sheet_1.pdf. 2018 ,		
28	Table_1.DOCX. 2019 ,		
27	Table_1.docx. 2018 ,		
26	Where Are We Now and Where Might We Be Headed in Understanding and Managing Brain Metastases in Colorectal Cancer Patients?. <i>Current Treatment Options in Oncology</i> , 2022 , 1	5.4	0

25	Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA. <i>Cancers</i> , 2022 , 14, 2479	6.6	1
24	Diagnostic role of NPY methylation in patients with colorectal cancer. 2022 , 52, 2		0
23	Liquid biopsy in der gastrointestinalen Onkologie: Hype oder bald Realität?. <i>Journal Fuer Gastroenterologische Und Hepatologische Erkrankungen</i> , 2022 , 20, 45-54		0
22	ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2022 ,	10.3	9
21	Circulating DNA in the neoadjuvant setting of early stage colon cancer. 1-7		1
20	Comparison of Droplet Digital PCR and Metagenomic Next-Generation Sequencing Methods for the Detection of Human Herpesvirus 6B Infection Using Cell-Free DNA from Patients Receiving CAR-T and Hematopoietic Stem Cell Transplantation. Volume 15, 5353-5364		0
19	The kinetics of circulating cell-free DNA to predict the clinical efficacy of first-line chemotherapy in patients with metastatic colorectal cancer.		0
18	NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer. 2022 , 14, 4459		0
17	A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01).		0
16	Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study. OF1-OF10		0
15	Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers Current evidence and future directions. 12,		0
14	Relapse and non-relapse prediction using a sensitive circulating tumor DNA assay during colorectal cancer postoperative surveillance.		0
13	Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients. 1-10		0
12	Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer. 12,		0
11	Integrative analysis of multi-omics data for liquid biopsy.		0
10	Liquid Biopsy. 2022 , 457-464		0
9	Recurrence risk assessment for stage III colorectal cancer based on five methylation biomarkers in plasma cell-free DNA.		0
8	Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA. 2023 , 15, 817		1

- 7 NPY methylated ctDNA is a promising biomarker for treatment response monitoring in metastatic colorectal cancer. ○
- 6 Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review. Volume 14, 11-25 ○
- 5 The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer. **2023**, 15, 1284 ○
- 4 Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation. **2023**, 15, 1473 ○
- 3 Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer. 102-138 ○
- 2 Enhancing clinical potential of liquid biopsy through a multi-omic approach: A systematic review. 14, ○
- 1 An Excellent Response of Microsatellite Instability-High Pancreatic Adenocarcinoma to Pembrolizumab Treatment: The Role of Circulating Tumor DNA Testing. **2023**, ○